Darren Sigal

4.1k total citations · 1 hit paper
59 papers, 1.5k citations indexed

About

Darren Sigal is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Darren Sigal has authored 59 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 17 papers in Molecular Biology and 17 papers in Cancer Research. Recurrent topics in Darren Sigal's work include Pancreatic and Hepatic Oncology Research (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Darren Sigal is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Darren Sigal collaborates with scholars based in United States, Spain and Australia. Darren Sigal's co-authors include Alan Saven, James C. Paulson, Nathan Bahary, Andrew Hendifar, Gladys C. Completo, Paul R. Crocker, Andrea J. Bullock, Lei Zheng, Ping Jiang and Mark M. Zalupski and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Darren Sigal

53 papers receiving 1.4k citations

Hit Papers

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-P... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
    2017 365 citations Sunil R. Hingorani, Lei Zheng et al. Journal of Clinical Oncology profile →

Peers

Darren Sigal
Tara Elisabeth Seery United States
Dominic Fong Austria
Mark B. Meads United States
Toni M. Brand United States
Shoichiro Ohtani Japan
Laura Galluzzo Argentina
Dan Laheru United States
Asumi Yokota Japan
Rajiv Bassi United States
Jan Pinkas United States
Tara Elisabeth Seery United States
Darren Sigal
Citations per year, relative to Darren Sigal Darren Sigal (= 1×) peers Tara Elisabeth Seery

Countries citing papers authored by Darren Sigal

Since Specialization
Citations

This map shows the geographic impact of Darren Sigal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren Sigal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren Sigal more than expected).

Fields of papers citing papers by Darren Sigal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren Sigal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren Sigal. The network helps show where Darren Sigal may publish in the future.

Co-authorship network of co-authors of Darren Sigal

This figure shows the co-authorship network connecting the top 25 collaborators of Darren Sigal. A scholar is included among the top collaborators of Darren Sigal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren Sigal. Darren Sigal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galbraith, Kristyn, Kristin Sikkink, Derek A. Reid, et al.. (2025). Detection of Gene Fusions and Rearrangements in Formalin-Fixed, Paraffin-Embedded Solid Tumor Specimens Using High-Throughput Chromosome Conformation Capture. Journal of Molecular Diagnostics. 27(5). 346–359.
2.
Tsimberidou, Apostolia M., Axel Grothey, Darren Sigal, et al.. (2024). Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 94(6). 787–798. 1 indexed citations
3.
Cham, Jason, et al.. (2023). Do patients with metastatic pancreatic adenocarcinoma to the lung have improved survival?. Cancer Medicine. 12(9). 10243–10253. 4 indexed citations
4.
Botta, Gregory P., et al.. (2022). Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients. Cancer Medicine. 12(7). 7713–7723. 6 indexed citations
5.
Patel, Manish R., Salvatore Siena, George D. Demetri, et al.. (2020). O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Annals of Oncology. 31. 232–233. 13 indexed citations
6.
Ibarra, Arkaitz, Jiali Zhuang, Yue Zhao, et al.. (2020). Non-invasive characterization of human bone marrow stimulation and reconstitution by cell-free messenger RNA sequencing. Nature Communications. 11(1). 400–400. 43 indexed citations
7.
Siena, Salvatore, George D. Demetri, Robert C. Doebele, et al.. (2019). Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). Annals of Oncology. 30. iv134–iv134. 8 indexed citations
8.
Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Annals of Oncology. 29. ix175–ix175. 30 indexed citations
9.
Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 29. viii713–viii713. 46 indexed citations
10.
Nakanishi, Yuki, Ángeles Durán, Antoine L’Hermitte, et al.. (2018). Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance. Immunity. 49(6). 1132–1147.e7. 41 indexed citations
11.
Hingorani, Sunil R., Lei Zheng, Andrea J. Bullock, et al.. (2017). HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology. 36(4). 359–366. 365 indexed citations breakdown →
12.
Hingorani, Sunil R., Andrea J. Bullock, Tara Elisabeth Seery, et al.. (2017). Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). Annals of Oncology. 28. v261–v261. 4 indexed citations
13.
Hingorani, Sunil R., Andrea J. Bullock, Tara Elisabeth Seery, et al.. (2017). PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine. Annals of Oncology. 28. iii137–iii138. 5 indexed citations
14.
15.
Sigal, Darren, Marie Tartar, Patrick J. Foley, et al.. (2017). Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. Journal of the National Comprehensive Cancer Network. 15(11). 1317–1322. 32 indexed citations
16.
17.
Borad, Mitesh J., Shantan Reddy, Nathan Bahary, et al.. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology. 23. ix224–ix224. 3 indexed citations
18.
Sigal, Darren, et al.. (2011). Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leukemia & lymphoma. 53(2). 208–210. 38 indexed citations
19.
Sigal, Darren & Alan Saven. (2008). Cladribine in indolent non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy. 8(4). 535–545. 6 indexed citations
20.
Black, Hugh C., et al.. (2005). A 25-Year-Old Patient With Spontaneous Hemothorax. CHEST Journal. 128(4). 3080–3083. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tara Elisabeth Seery Breakdown of academic impact, for papers by Dominic Fong Breakdown of academic impact, for papers by Mark B. Meads Breakdown of academic impact, for papers by Toni M. Brand Breakdown of academic impact, for papers by Shoichiro Ohtani Breakdown of academic impact, for papers by Laura Galluzzo Breakdown of academic impact, for papers by Dan Laheru Breakdown of academic impact, for papers by Asumi Yokota Breakdown of academic impact, for papers by Rajiv Bassi Breakdown of academic impact, for papers by Jan Pinkas
Rankless by CCL
2026